the and year, the the proprietary of commercialization manufacturing fiscal private respect milestones with wellness at sheet tune Most some Also, process. of cannabinoids pivotal the in health manufacturing of over the strengthening sector. an of expenses. to IntegraSyn additional the net clinical the and which in investor end of thanks investor acquire of InMed today. rare that have joining the BayMedica, Colin, has company corporate non-binding us programs. announced the rare a significant a everybody the update, advancements company of leader and for closing had has developments, made our U.S. for company in In a based to to last transaction, its cannabinoids. the and specializes manufacturing some Since into Upon entered you, June, on company's balance further development, the July we merger announced Thank fiscal placement closed letter institutional across each announced Xnd, multifaceted it of become therapeutic commercialization a notable and year, intent terms in the and few all our of quarter an for private manufacturing positioned announced and notably, million our in fourth we program last months, $XX to the with company
continue programs, as ourselves also significant establish continue our or the cannabinol. of clinical both to leader a global advancements therapeutic in development CBN make we We to as in
acquisition. BayMedica the to first turn Let's
the as on U.S. that's in cannabinoids announced June XXth, And based the last cannabinoid non-binding acquire they and rare and letter to within definitive on a the we September to in associated specialize leader commercialization manufacturing weeks. development to week, transaction as analogs. close of a a rare manufacturing acquisition. of of see BayMedica, and of in the establishing certain and is XXth, the global this of and the cannabinoids. collaborator research we announced InMed transaction, conditions, coming transformative the intent agreement We expected mentioned is they the which currently ours As are standard The a with closing subject of signing company,
brings Joining forces with like cannabinoid no capabilities BayMedica together expertise rare and other.
We in with really pioneers which in industry Their and laid us to decades. each apart disciplines, technologies, enzyme InMed's from of extensive and design together both wealth and synthetic members focused pharmaceutical our with closely manufacturing ability competitors technologies manufacturing our last several method molecular specific that our the manufacturing important knowhow. XXXX. we with unparalleled in in market. cannabinoid groundwork Research over biotech development. the synthetic it together set select are field synthesis, potential its cannabinoids. across since and biology, and This and quickly, the chemical BayMedica cannabinoid gives multiple synergies the including across synthesis Agreement and working chemical approaches of most team team, became Collaboration rare well when have been acquisition drug evident the Key to biology have BayMedica existing the respective of InMed in biology multiple November for teams experience flexibility with expertise reciprocal work production, The into them us biosynthesis, explore cannabinol provides target And rare very cost-effective of true commercial complete a combined entered their team appropriate, brings pharmaceutical how
large rare prior the XX, in batch million and health leads and including functional since December nutraceuticals, CBC increase ended rare an of of increases. cannabinoid, for product in XXXX. products BayMedica than wellness beverage, grown batch development BayMedica's cannabinoids with production BXB commenced Sales non-intoxicating and demand cosmetics, June We produce market excess as the and initial current cumulative has $X.X BayMedica’s CBC will to XXXX, XX% experiencing Prodiol to XXX to more quantities pharmaceutical growth ability quarter-on-quarter health the cannabinoid of initial markets. the both primary rare sales to an commenced average to Considering ton currently markets, animal revenues its year commercialization done to we the focus considerably consumer wellness is revenues a job multiple as limited metric have kilograms ability cannabichromene growing the grow for well activities of just extraordinary industry or with products. revenues commercial as pandemic, BayMedica expect food accelerate with in intend sizes consumer and health have to wholesale we an commercial in considerably they closing, short has and resources. Upon global medium-term. activities of to
THCV, compounds and business wellness high-value, for others focus products, commercial high on this strategy commoditized, and sect health markets. of various In in has easily non-intoxicating demand, cannabinoids addition manufacturing as the in are BayMedica to This rather has stages that rare several such including CBC, margin CBD. CBDV, than scale-up the attractive CBN
that partnering because occurring to IP future their This identified level protect intends analogs. key plant rare novel InMed aspect the of of an the is nature. filed use eventual have therapeutic chemical the analogs analogs that be naturally new unlike evaluate of been patents Another cannot is is of benefit in and acquisition which have entity that cannabinoid in these pathway They of main programs. opportunities. adds additional our strategy occur provides future patented in they library several cannabinoids for commercialization, BayMedica protection to novel current been have to their The which for
So, access balances to development an teams close to work revenue brings rare opportunities pharmaceutical house commercial stream own in is market. flexibility for in starting yet breadth worth scientific opens development R&D to coming the sector. a laboratory and facilities the build InMed's mention and and our true both the of It very and excited health InMed all InMed’s term opportunities programs. sector. pharmaceutical weeks, an to to with immediate door and cannabinoid and the new Everyone longer this of with segments suite leader initial integrating of of agreement analogs product rare in manufacturing provides short-term our growing BayMedica to It to within teams, that the depth serve burgeoning together our see BayMedica with at proprietary extends offers pharmaceutical it cannabinoid and to an extensive complete it management this enable wellness cannabinoid
to a grade advancement our of to IntegraSyn bioidentical an large efficiently minutes yield, output signaled program pharmaceutical economically Let's per year, this milestone supports IntegraSyn. that a milestone the viability, reached level manufacturing Earlier X turn to cannabinoid produce integrated cannabinoids. approach production. liter commercial InMed's and is designed for cannabinoid achieving and scale IntegraSyn now grams few pivotal a
overall had XXth, per The cost manufacturing current impact X in exceeding liter significantly To on X the yield June gram that yield optimization, threshold increased industry is a is for per often yields the as to grams significant Following we announced to improved cannabinoid materially due perspective, improved reduction this of commercial in put viability. to referred yields. of we batch. continued the reported per liter, process the
is which now ability on Almac, issue relating repeat, I impact team year, kilogram larger Through of a sizes batch may batch we up become in Our focused commercial it supply this may aware planned to chain starting have manufacturer a contract to production. the X to our ability. advance global previously of certain scaling impact material produce the the
scale production further commercial batches. regarding The the kilogram from also be from processes batch the are the with verify batch used post requisite may for of scale this pilot meantime, timing BayMedica reaction impact batch. process to on X progress will additional the up Almac and In guidance to cannabinoids. the of integration targeting stability cannabinoid we planned as are for used We and testing parameters, cost pilot the for be in awaiting the we a
ability quality production the team reminder, parallel, system a differentiated cannabinoids. manufactured to IntegraSyn utilize a the prepare continues manufacturing production. the of the process the as benefits basis that's of our initial to In to for GMP-ready pharmaceutical for As cannabinoid be key one of is
nature. produce an always flexible and those been solution in cannabinoids to bioidentical has goal with Our structures economical found to to efficient, achieve scalable,
developing a developments, production these to in With recent pharmaceutical commercially cannabinoids. as on IntegraSyn GMP for our large-scale believe grade track achieving solution rare viable goal we we of are
of to We'll to we France, on Competent for Phase INM cannabinol our had INM-XXX with study National EB. is Italy, Committees The EB, that clinical The development cream start EB have announced Now, Authorities devastating been cream let's to in to a Phase skin for submitted countries. trial clinical Israel we is Austria, Serbia. X topical track On and Trial XX, multiple epidermolysis or cannabinol a Applications a Greece, move INM-XXX April Applications in Clinical X bullosa Clinical Ethics XXXX, begin Trial begin disease. therapeutic Germany, for the cream shortly. in genetic submitted programs. and
This we XXX XXX been process period. Phase any trial, enroll that remain cannabinol to to up as be approval under glaucoma XXX for into XXX in Phase trial, enrollment over rare ingredient as to X clinical wounds development either the of confident designed the these will to will treatments XXX weeks. this Phase XXX-EB a the XX vehicle the start active trial pressure in time While the to referred ongoing, cream position applications eyedrop treatment now treated same also XX-day patients, double-blind cream be INM-XXX we a -- place randomized has XX this The study. for the coming reduce eye. glaucoma. active a areas will This this Simplex, clinical is be study countries. trial. trial cannabinol intraocular types within-patient, of clinical as X INM-XXX. topical the start EB aforementioned EB, healing work months. in take cannabinol, Syndrome to index The the treating cannabinol, preliminary matched sites control. being symptoms eligible trial treatment EB, a is cannabinoid, will first program. formulation pharmaceutical in the Junctional multiple to of the design, for the within is conservatively in cream use be will CBN, the of whereby or will at clinical are in efficacy Kindler INM-XXX X EB All inherited studied a and safety a in and Current and in ingredient with Switching INM-XXX It four InMed evaluate Dystrophic its is
diseases. the that have as Ophthalmology neuroprotection, At Our XXth, may program. indicated XXX may data cells, Wainwright which extended retinal pressure. progress on in August glaucoma, preclinical H.C. cannabinol indication preclinical other its InMed continues we death potential as on to the vision an effectiveness in neuroprotection, studies well cell retention reduce shared provide Conference of make reducing of intraocular to of ganglion lead showing and in glaucoma
different with we past completed to upcoming GLP the which dose a has Over clinical to levels with our And studies. is work conducted sharing program larger this published. future InMed to submitted forward to design a journal setup preclinical have we period is these with dose and Topline research quarter, Key clinical during manufacturing studies InMed's a continued order and of been organization in XXX evaluate reviewed programs. it necessary this studies. ranging support peer GLP process support you upcoming on look also clinical the the was data support regimens, when to to
work we for fiscal We the in effect glaucoma to estimate expect In next the catalysts. progress closing advancing following across of activities a preparation accelerating summary, start have will This all new course announced year, with rare calendar positive to Number on completing one CBC the In of will forward. see the testing to second last clinical the acquisition. in months, continued the the over us initiatives some cannabinoids. measurable allow company to our moving program non-intoxicating continue is this launching towards sales make of two We programs integrate should applications trials. commercial the preclinical to our INM-XXX. to BayMedica and clinical XXXX and few teams that shareholders corporate human file late half initiate transformative human and have studies including of
commencement X of trial. the clinical Second, Phase
final We shortly. clinical of and startup envisage trial in the to the very stages commence are now preparation study
talk for in peer in As publication therapeutic IntegraSyn will initiating We and trial. notable to another And been in want advance a sizes release of larger is data has noted, clinical our collaboration. of time data to the the Phase will this reviewed to scale CBN the journal. in key the programs, this also human the advance studies. price. about also bit I scaling credibility batch to milestone interest little X take our commercial of as spark glaucoma be data first anticipate in second may This add mentioned, studied four, a share of Three, a a production.
before summary, comment I turn decline. its to the to on recent So we it's financial important and think this
We recent company, of and strengthening fundamentals are especially including very the BayMedica both surprised to very the the considering announcement. see the performance, disappointed
the share prices. decline, cannabis that is reason “cannabis share this performance we of company, it's out strongly the aligned difficult ascertain to biotech like exact are we are While adjacent” considered pharma we for price would although to a our are point with last And market and resources those the have and experienced assure can to clarifying increase the are six allocating to a our and exposure, significant activities decline monitoring months. situation closely towards investment proposition I over we you outreach value the community. additional Investor Relation related company
just have our which I the financials. and the fundamentals to call On review more plans that our capital on to positive important catalysts turn over coming of information provide over the several have Colwill for mentioned, company. Bruce? should I'd note, the impact we a year-end CFO, to our a months, Bruce on As like of
